195. ヌーナン症候群 Noonan syndrome Clinical trials / Disease details
臨床試験数 : 25 / 薬物数 : 23 - (DrugBank : 5) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02713945 (ClinicalTrials.gov) | January 25, 2017 | 9/3/2016 | Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome | Treatment With HMG-COA Reductase Inhibitor (Simvastatin) of Growth and Bone Abnormalities in Children With Noonan Syndrome: A Phase III Randomised, Double Blind, Placebo-controlled Therapeutic Trial | Noonan Syndrome | Drug: Simvastatin;Drug: Placebo | University Hospital, Toulouse | NULL | Completed | 6 Years | 16 Years | All | 53 | Phase 3 | France |
| 2 | EUCTR2016-000647-14-FR (EUCTR) | 23/05/2016 | 30/03/2016 | Treatment with simvastatin of growth and bone abnormalities in children with Noonan syndrome | Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial - RASTAT | Noonan syndrome;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Trade Name: Simvastatin Product Name: Simvastatin | University Hospital Toulouse | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 62 | Phase 3 | France |